Mirabegron

Overactive Bladder Syndrome, Neurogenic Detrusor Overactivity, Obesity
Treatment
2 FDA approvals
20 Active Studies for Mirabegron

What is Mirabegron

MirabegronThe Generic name of this drug
Treatment SummaryMirabegron is a medication that relaxes the bladder muscles to help with urinary frequency and incontinence. It is different from other treatments because it doesn’t have the same range of side effects as other medications. It was approved by the FDA in 2012 and can be used to treat adults with overactive bladder. In 2021, an extended-release granule formulation was approved for pediatric patients with neurogenic detrusor overactivity. Mirabegron is also used in other countries like Canada, the European Union, and Japan.
Myrbetriqis the brand name
image of different drug pills on a surface
Mirabegron Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Myrbetriq
Mirabegron
2012
8

Approved as Treatment by the FDA

Mirabegron, also known as Myrbetriq, is approved by the FDA for 2 uses which include Overactive Bladder Syndrome (OABS) and Overactive Bladder Syndrome .
Overactive Bladder Syndrome (OABS)
Used to treat Overactive Bladder Syndrome (OABS) in combination with Solifenacin
Overactive Bladder Syndrome
Used to treat Overactive Bladder Syndrome (OABS) in combination with Solifenacin

Effectiveness

How Mirabegron Affects PatientsMirabegron relaxes the bladder muscles, allowing the bladder to hold more urine and decreasing urgency. It has been reported to cause urinary retention in people with bladder outlet obstruction, so should be used with caution in these patients. Mirabegron also increases both blood pressure and heart rate, which can be dangerous for those with uncontrolled hypertension, so should also be used with caution in these cases.
How Mirabegron works in the bodyMirabegron is a drug that relaxes the muscles of the bladder, allowing it to hold more urine. This can help relieve feelings of urgency and the need to go to the bathroom frequently.

When to interrupt dosage

The proposed measurement of Mirabegron is contingent upon the diagnosed state, for example Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome and weight no less than 35 kg. The amount likewise fluctuates relying upon the approach of delivery (e.g. Granule, for suspension, extended release - Oral or Tablet, extended release - Oral) indicated in the table beneath.
Condition
Dosage
Administration
Overactive Bladder Syndrome
, 25.0 mg, 50.0 mg, 8.0 mg/mL
Oral, Tablet, extended release - Oral, , Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release
Neurogenic Detrusor Overactivity
, 25.0 mg, 50.0 mg, 8.0 mg/mL
Oral, Tablet, extended release - Oral, , Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release
Obesity
, 25.0 mg, 50.0 mg, 8.0 mg/mL
Oral, Tablet, extended release - Oral, , Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release

Warnings

Mirabegron Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Mirabegron may interact with Pulse Frequency
There are 20 known major drug interactions with Mirabegron.
Common Mirabegron Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Mirabegron.
Axitinib
Major
The serum concentration of Axitinib can be increased when it is combined with Mirabegron.
Bendamustine
Major
The serum concentration of Bendamustine can be increased when it is combined with Mirabegron.
Binimetinib
Major
The serum concentration of Binimetinib can be increased when it is combined with Mirabegron.
Cabazitaxel
Major
The serum concentration of Cabazitaxel can be increased when it is combined with Mirabegron.
Mirabegron Toxicity & Overdose RiskTaking too much of this drug can cause racing heartbeats and an increased heart rate. Long-term overdoses may also cause a rise in blood pressure. If someone overdoses on this drug, they should be monitored by an ECG and receive supportive treatments to help reduce any symptoms.
image of a doctor in a lab doing drug, clinical research

Mirabegron Novel Uses: Which Conditions Have a Clinical Trial Featuring Mirabegron?

33 active clinical trials are currently being conducted to explore the possible benefits of Mirabegron in treating Neurogenic Detrusor Overactivity, weight at least 35 kg and Overactive Bladder Syndrome.
Condition
Clinical Trials
Trial Phases
Obesity
0 Actively Recruiting
Overactive Bladder Syndrome
29 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 1, Phase 2
Neurogenic Detrusor Overactivity
3 Actively Recruiting
Phase 2, Phase 3, Phase 1

Mirabegron Reviews: What are patients saying about Mirabegron?

5Patient Review
1/25/2013
Mirabegron for Overactive Bladder
5Patient Review
5/25/2013
Mirabegron for Overactive Bladder
This medication is much cheaper than having a surgical implant, and it works just as well for me. The only downside is that it's still pretty pricey.
5Patient Review
7/10/2015
Mirabegron for Urine Leakage When there is a Strong Desire to Void
Worked great with no real side effects to speak of. The only problem is that it's quite expensive--$116 a month.
4.7Patient Review
6/26/2014
Mirabegron for Overactive Bladder
I had leakage and urgent incontinence/flooding. Detrol was effective but dry mouth was horrible. Mirabegron has worked almost as well and with no side effects.
4.3Patient Review
7/27/2016
Mirabegron for Overactive Bladder
I was pleasantly surprised at how quickly this medication worked. However, I developed an upset stomach as a result of taking it. This seems to be a common side effect, but it's still worth mentioning.
4Patient Review
6/29/2013
Mirabegron for Overactive Bladder
I've tried so many different medications for incontinence, and this one was by far the most effective. I only had to get out of bed once during the night, which is a huge improvement from before.
3.7Patient Review
1/18/2020
Mirabegron for Overactive Bladder
I've been taking Mirabegron for a while now and it's helped me a lot. It's definitely my preferred choice of medication, but I had to stop taking it for a couple months because I started developing a skin rash about six months ago. Not sure if it was the Mirabegron or not, but that is one of the potential side effects so I figured it was best to be safe.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about mirabegron

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the best time to take mirabegron?

"You can take mirabegron at any time of day, but try to take your doses at the same time of day each day to avoid missing doses. Swallow the tablet with a drink of water."

Answered by AI

What type of drug is mirabegron?

"Paraphrase:

Mirabegron belongs to a class of medications called beta-3 adrenergic agonists. These drugs work by relaxing the muscles in the bladder, which prevents frequent or uncontrolled urination."

Answered by AI

What is the drug mirabegron used for?

"a strong need to pee often (urinary frequency)

leaking urine (urinary incontinence)

waking up at night to urinate (nocturia)

Mirabegron eases the symptoms of overactive bladder but does not cure the condition. Symptoms it alleviates include:

sudden and urgent need to urinate

frequent need to urinate

urinary incontinence

waking up at night to urinate"

Answered by AI

What are the side effects of taking mirabegron?

"The following are symptoms of a bladder infection: bladder pain, bloody or cloudy urine, difficult, burning, or painful urination, frequent urge to urinate, pounding in the ears, slow, fast, or irregular heartbeat."

Answered by AI

Clinical Trials for Mirabegron

Image of Neighborhood Healthcare in Escondido, United States.

Cagrilintide + CagriSema for Childhood Obesity

8 - 18
All Sexes
Escondido, CA
This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants who get semaglutide in the main study will not take part in the extension study. If participants take part in the extension study, they will get either CagriSema or cagrilintide in this part of the study. Like all drugs, the study drugs may have side effects. The total time participants will be in the main study is about 1 year and 6 months. If participants take part in the extension study, the total time is about 4 years and 10 months.
Phase 3
Waitlist Available
Neighborhood Healthcare (+30 Sites)Clinical Transparency (dept. 2834)Novo Nordisk A/S
Have you considered Mirabegron clinical trials? We made a collection of clinical trials featuring Mirabegron, we think they might fit your search criteria.Go to Trials
Image of UConn Health in Farmington, United States.

Digital Exercise Prescription Tool for Cardiovascular Disease

18 - 64
All Sexes
Farmington, CT
The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.
Waitlist Available
Has No Placebo
UConn Health (+2 Sites)Linda S Pescatello, PhD
Have you considered Mirabegron clinical trials? We made a collection of clinical trials featuring Mirabegron, we think they might fit your search criteria.Go to Trials
Image of St. Jude Children's Research Hospital in Memphis, United States.

Tirzepatide + Resistance Exercise for Obesity in ALL Survivors

18+
All Sexes
Memphis, TN
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of childhood ALL with obesity or overweight (BMI ≥27 kg/m2) with ≥1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The effectiveness will be estimated as the proportion of evaluable participants who achieve at least 5% weight loss from baseline to week 28. The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable. Secondary Objective(s): * Estimate the proportion of participants who adhere to the 28-week combined intervention. Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint. The adherence to each component of the intervention will also be reported. * Estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention. The study will target a mean weight reduction of 10% and consider \<5% unacceptable.
Phase 2
Waitlist Available
St. Jude Children's Research HospitalStephanie B Dixon, MD, MPH
Have you considered Mirabegron clinical trials? We made a collection of clinical trials featuring Mirabegron, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security